The Value Proposition: Justifying the Investment in HS Centers of Excellence

Panelist discusses how organizations can justify the cost of Centers of Excellence for HS by improving patient outcomes, reducing complications, and enhancing care efficiency. Metrics for evaluating multidisciplinary care include patient satisfaction, quality of life, clinical improvements, and reduction in hospitalizations.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

Now Viewing

EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence

EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

EP: 12.Navigating HS Management: The Patient Journey

EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement

EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

• How can organizations justify the effort/cost of establishing Centers of Excellence for HS?
• What metrics should be used to evaluate the effectiveness of multidisciplinary care in improving outcomes for HS patients?

Related Videos

Related Content

Advertisement

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 26th 2025

Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B

Julia Bonavitacola

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Related Content

Advertisement

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 26th 2025

Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B

Julia Bonavitacola

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.